On November 29, 2023, the final of the China Future Health Entrepreneurship Competition of the MIT Technology Review concluded in Hangzhou Future Sci-Tech City. As a newly established company just 8 months ago, Hangzhou Intag Biosciences LLC. was honored to receive the "Emerging Award of the Year".

In this competition, Dr. Pan Pengkai, CEO of Intag Biosciences LLC, presented a topic titled "Leading the Next Generation of POCT Molecular Diagnostics," introducing a groundbreaking direction for the future of POCT molecular diagnostics, which received widespread acclaim from the onsite judges. Among the judges were academicians such as Tan Weihong, Academician of the Chinese Academy of Sciences, Academician of the Developing Countries Academy of Sciences, Director of the Hangzhou Institute of Medical Research at the Chinese Academy of Sciences, and Dean of the Institute of Molecular Medicine at Shanghai Jiao Tong University; Yang Huanming, Academician of the Chinese Academy of Sciences, Member of the Academy of Medical Sciences of China, Professor at the University of Chinese Academy of Sciences and China Union Medical College, Vice Chairman of the Chinese Society of Genetics, the Chinese Society of Biotechnology, and the Chinese Urban Science Research Association, and Co-founder of BGI Group in Shenzhen; as well as Zhang Hangjun, Member of the Party Committee and Vice President of Hangzhou Normal University, among others. They unanimously agreed that "Intag Biosciences designs next-generation high-efficiency polymerases, develops rapid, convenient, multiplex, and precise molecular detection core technologies, empowering IVD companies worldwide."

Hangzhou Intag Biosciences LLC. was founded in 2023, committed to providing fast, convenient, and accurate product solutions for molecular POCT detection, based on innovative nucleic acid instant testing technology. To empower the global molecular diagnostic industry with effective tools and solutions.